Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry.
Fiche publication
Date publication
septembre 2023
Journal
Blood advances
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr RUBIO Marie Thérèse
Tous les auteurs :
Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Di Blasi R, Rubio MT, Guidez S, Mohty M, Casasnovas O, Joris M, Castilla-Llorente C, Haioun C, Hermine O, Loschi M, Carras S, Bories P, Fradon T, Herbaux C, Sesques P, Le Gouill S, Morschhauser F, Thieblemont C, Houot R
Lien Pubmed
Résumé
CD19 chimeric antigen receptor (CAR) T-cells can induce prolonged remissions and potentially cure a significant proportion of patients with relapsed/refractory (r/r) large B-cell lymphomas (LBCL). However, some patients may die of causes unrelated to lymphoma after CAR T-cell therapy. To date, little is known about the non-relapse mortality (NRM) following CAR T-cells. Using the French DESCAR-T registry, we analyzed the incidence and causes of NRM, and identified risk factors of NRM. We report 957 patients who received standard-of-care (SOC) axicabtagene ciloleucel (axi-cel; n=598) or tisagenlecleucel (tisacel; n=359) between July 2018 and April 2022, in 27 French centers. With a median follow-up of 12.4 months, overall NRM occurred in 48 patients (5.0% of all patients): early (
Référence
Blood Adv. 2023 09 6;: